Figure 2.

ImmunoPET imaging and ex vivo biodistribution data delineate lymph node involvement in mice bearing OVCAR3 xenografts. A–D, Maximum intensity projection (MIP) PET-CT images (scaled 0–100) of mice with subcutaneous OVCAR3 xenografts acquired 5 days after the intravenous administration of 1.2 ± 0.1 mg/kg of [⁸⁹Zr]Zr-DFO-muAR9.6 (255 ± 49.5 μCi; 9.4 ± 1.8 MBq; 29.6 ± 2.0 μg) showing differing distributions of radioactivity. Heterogeneous patterns of uptake are evident in the tumor (T), lymph nodes (ALN = axillary lymph node; BLN = brachial lymph node; CLN = cervical lymph node; ILN = inguinal lymph node), blood (indicated by the heart, H), and liver (L). E,Ex vivo biodistribution data comparing the radioactivity concentrations (%ID/g) in the IALNs, CALNs, and subcutaneous tumors of the tumor-bearing mice whose biodistribution data were reported in Fig. 1F. F, Graph comparing the percentage of total injected dose (%ID) values for the IALN and CALN at 5 d p.i. in the OVCAR3 tumor-bearing mice whose biodistribution was shown in Fig. 1F. G,Ex vivo MIP PET image of the tumor, IALNs, and CALNs collected from an OVCAR3-bearing xenograft 7 days after the administration of 1.2 ± 0.1 mg/kg of [⁸⁹Zr]Zr-DFO-muAR9.6 (255 ± 49.5 μCi; 9.4 ± 1.8 MBq; 29.6 ± 2.0 μg). H, H&E-stained IALN from mouse depicted in Fig. 2D revealing no signs of overt infiltration by neoplastic cells. Detailed sets of %ID/g and %ID values are provided in Supplementary Tables S3 and S4. The maximum intensity projections have been scaled from 0% to 100%.